Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | HPGD | P15428 | 3/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | PDXK | O00764 | 3/20 | 0.61 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.61 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29733341 | 1.00 | KDM4E (0.66) | KDM4EALDH1A1HPGDHSD17B10PDXK | |
| SCHEMBL1049253 | 0.98 | KDM4E (0.68) | KDM4EALDH1A1HPGDHSD17B10PDXK | |
| Hydrochloric Acid SCHEMBL28098773 | 0.94 | KDM4E (0.63) | KDM4EALDH1A1HPGDHSD17B10PDXK | |
| SCHEMBL3442719 | 0.83 | KDM4E (0.70) | KDM4EALDH1A1HPGDHSD17B10PDXK | |
| Pyridoxine SCHEMBL7588196 | 0.82 | KDM4E (0.96) | KDM4EALDH1A1HPGDHSD17B10PDXK | |
| Hydrochloric Acid SCHEMBL11450712 | 0.82 | ALDH1A1 (0.48) | KDM4EALDH1A1HPGDHSD17B10PDXK | |
| Pyridoxine SCHEMBL42293 | 0.82 | KDM4E (0.96) | KDM4EALDH1A1HPGDHSD17B10PDXK | |
| Pyridoxine SCHEMBL3383552 | 0.82 | KDM4E (0.96) | KDM4EALDH1A1HPGDHSD17B10PDXK | |
| Pyridoxine SCHEMBL15769549 | 0.82 | KDM4E (0.96) | KDM4EALDH1A1HPGDHSD17B10PDXK | |
| Pyridoxine SCHEMBL444525 | 0.82 | KDM4E (0.96) | KDM4EALDH1A1HPGDHSD17B10PDXK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3101407-B1 | KIT AND METHOD FOR ELECTRON MICROSCOPE OBSERVATION | JAPAN SCIENCE & TECH AGENCY (JP) | 2023-03-08 | — | — | EP | disclosed |
| CN-115279420-A | Polyol-based polydixylitol gene transporter containing cancer stem cell specific binding peptide and binding with vitamin B6, and cancer stem cell targeted therapy technology | 埃尔比奥股份有限公司 | 2022-11-01 | — | — | CN | disclosed |
| US-10544140-B2 | Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof | LG CHEM, LTD. (KR) | 2020-01-28 | — | — | US | disclosed |
| US-20180370964-A1 | PHARMACEUTICAL COMPOSITION CONTAINING, AS ACTIVE INGREDIENT, 7-AZAINDOLIN-2-ONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | LG CHEM, LTD. (KR) | 2018-12-27 | — | — | US | disclosed |
| US-10128078-B2 | Protective agent for electron microscopic observation of biological sample in water-containing state, kit for electron microscopic observation, methods for observation, diagnosis, evaluation, and quantification by electron microscope, and sample stage | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2018-11-13 | — | — | US | disclosed |
| EP-3363799-A1 | PHARMACEUTICAL COMPOSITION CONTAINING, AS ACTIVE INGREDIENT, 7-AZAINDOLIN-2-ONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | LG Chem, Ltd. (KR) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017082569-A1 | PHARMACEUTICAL COMPOSITION CONTAINING, AS ACTIVE INGREDIENT, 7-AZAINDOLIN-2-ONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 영남대학교 산학협력단 | 2017-05-18 | — | — | WO | disclosed |
| EP-2755225-B1 | ELECTRON-MICROSCOPIC EXAMINATION METHOD FOR EXAMINING A LIVING BIOLOGICAL SAMPLE | JAPAN SCIENCE & TECH AGENCY (JP) | 2017-05-10 | — | — | EP | disclosed |
| US-9557253-B2 | Electron microscopic observation method for observing biological sample in shape as it is, and composition for evaporation suppression under vacuum, scanning electron microscope, and transmission electron microscope used in the method | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2017-01-31 | — | — | US | disclosed |
| EP-3101407-A1 | PROTECTANT FOR ELECTRON MICROSCOPE OBSERVATION OF HYDRATED BIOLOGICAL SAMPLE, KIT FOR ELECTRON MICROSCOPE OBSERVATION, METHOD FOR OBSERVATION, DIAGNOSIS, EVALUATION, OR QUANTIFICATION BY ELECTRON MICROSCOPE, AND SAMPLE STAGE | Japan Science And Technology Agency (JP) | 2016-12-07 | — | — | EP | disclosed |
| CN-1733725-A | Process for preparing 2-iminopyrrolidine derivatives | EISAI CO LTD (JP) | 2006-02-15 | — | — | CN | disclosed |
| EP-1606295-A1 | HETEROARYL PHOSPHONATES, COMPOSITIONS CONTAINING THEM AND METHODS OF TREATMENT OF VARIOUS DISORDERS USING THEM | Medicure Inc. (CA) | 2005-12-21 | — | — | EP | disclosed |
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050113340-A1 | 2-Aminopurine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION | 2005-05-26 | — | — | US | disclosed |
| WO-2005028434-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| WO-2004083222-A1 | NOVEL HETEROARYL PHOSPHONATES AS CARDIOPROTECTIVE AGENTS | MEDICURE INC. (CA) | 2004-09-30 | — | — | WO | disclosed |
| US-20040186077-A1 | Novel heteroaryl phosphonates as cardioprotective agents | MEDICURE INTERNATIONAL INC. (BB) | 2004-09-23 | — | — | US | disclosed |
| CN-1503784-A | 2-iminopyrrolidine derivatives | ������������ʽ���� | 2004-06-09 | — | — | CN | disclosed |
| EP-1391451-A1 | 2-IMINOPYRROLIDINE DERIVATES | Eisai Co., Ltd. (JP) | 2004-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180370964-A1 | PHARMACEUTICAL COMPOSITION CONTAINING, AS ACTIVE INGREDIENT, 7-AZAINDOLIN-2-ONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | HDAC6, AZI2, HDAC7 | GAA 1574/4885KDM4E 1123/4885ALDH1A1 1515/4885 |
| US-20040186077-A1 | Novel heteroaryl phosphonates as cardioprotective agents | TNNT2, TNNI3, ADRB3 | GAA 3705/4885KDM4E 1894/4885ALDH1A1 3091/4885 |
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | GAA 4867/4885KDM4E 3161/4885ALDH1A1 443/4885 |
| US-10544140-B2 | Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof | AZI2, HDAC7, CYP3A7 | GAA 983/4885KDM4E 1362/4885ALDH1A1 780/4885 |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | GAA 4868/4885KDM4E 3132/4885ALDH1A1 437/4885 |
| US-20050113340-A1 | 2-Aminopurine analogs having HSP90-inhibiting activity | HSP90AB2P, HSP90AB1, HSP90AA1 | GAA 788/4885KDM4E 3577/4885ALDH1A1 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.